Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151


Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS.

J Virol. 1999 Jul;73(7):5981-93.


CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2008 Sep 15;181(6):4406-17.


In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.

Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS.

J Immunol. 2003 Jul 15;171(2):697-707.


Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.

Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2005 Jul 15;175(2):700-12.


Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells.

Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, Reimann J.

J Immunol. 2002 Jan 1;168(1):108-17.


Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS.

J Virol. 1995 Nov;69(11):6665-77.


IL-12 treatment of endogenously arising murine brain tumors.

Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM.

J Immunol. 2000 Dec 15;165(12):7293-9.


Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.

Romieu R, Baratin M, Kayibanda M, Lacabanne V, Ziol M, Guillet JG, Viguier M.

J Immunol. 1998 Nov 15;161(10):5133-7.


Supplemental Content

Support Center